Industry Trends

Asia Pacific Gene Editing Market share was valued at USD 806 million in 2019 and is expected to witness 15.2% CAGR from 2019 to 2026.

Get more details on this report - Request Free Sample PDF

Technological advancements and innovations in gene editing in developing economies will augment the market growth. Researchers have developed advanced systems using alternative gene editing technologies to generate genetically engineered mice that were developed much faster as compared to traditional targeted mutation systems. CRISPR/Cas9 method is considered to be dominant over ZFNs and TALENS. The CRISPR/Cas9 technology has attracted significant attention of scientists due to its several advantages in gene editing and considered it to be a powerful therapeutic tool for treating diseases associated with genome mutations. However, the CRIPSR/Cas9 technology is also being improvised, and newer additions have further improved its functional capabilities with reduced off-target effects.

Asia Pacific Market, By Application

The Asia Pacific application segment covers plant genetic engineering, cell line engineering, and animal genetic engineering among others. Animal genetic engineering segment accounted for more than USD 224 million revenue size in 2019. Animal genetic engineering has the potential to greatly improve the welfare and health of agricultural animals. Animal genetic engineering produce more nutritious meat by altering animal proteins. Increasing consumption of products such as meat obtained from domestic animals will surge the demand for gene editing technique. Wide applicability of animal genetic engineering in prevention of several veterinary diseases will provide significant growth opportunities.

Asia Pacific Market, By Technology

On the basis of technology, the gene editing market is classified into TALENs, Zinc Finger Nucleases (ZFNs), CRISPR/Cas9 and others. TALENs segment was valued around 17% market share in 2019. TALENs technology is widely useful for efficient and precise gene editing in live cells. TALENs technology also offers a significant advantage for organizations that require a clear licensing path for commercial applications. Also, TALENs are an efficient option as it can create a cleavage site anywhere in the genome. TALENs have extensive applications in plant and animal genetic engineering. TALENs modifications can be engineered in fruit flies, zebrafish, nematodes, monarch butterflies, livestock and rats. Increasing benefits of TALENs technology in gene editing will prove beneficial for segment growth.

Asia Pacific Market, By End-user

Get more details on this report - Request Free Sample PDF

The gene editing end-user segment is divided into biotech & pharma companies, research institutes and contract research organizations. The biotech and pharma companies segment is anticipated to witness more than 14.8% CAGR during the analysis timeframe. Increasing funding will enhance the research and development of gene editing technologies. This funding will enable biotech and pharmaceutical companies to develop technologies for therapies using gene editing to treat and diagnose chronic disorders. The surging prevalence of chronic disorders such as cancer will boost the research activities, creating demand for biotech and pharma companies to develop gene editing therapies.

Asia Pacific Market, By Country

The Japan gene editing market held more than USD 288 million market value in 2019. Increasing funding for genome editing in developing countries such as Japan will offer lucrative growth opportunities. Due to several advantages associated with genome editing, various organization are supporting academic as well as research institutes for increasing research activities for genome editing. Implementation of guidelines for various several gene editing technologies to make precise modifications in DNA will foster the demand for gene editing therapies. In 2018, Japan received specific guidelines on using CRISPR-Cas9 gene technology in human embryos. Thus, above mentioned factors will propel the country growth.

Competitive Market Share

Some of the prominent players functioning in market are Thermo Fisher Scientific, EMD Millipore (Merck KGAa), Origene Technologies, Integrated DNA Technologies, Agilent Technologies, Takara Bio, CRISPR Therapeutics, Horizon Discovery Ltd and others. These market players are adopting strategies such as expansion and product innovations to expand their customer base and maintain financial stability. For instance, in April 2019, GenScript Corporation launched single-stranded DNA services for CRISPR-based gene-editing. This strategy helped the company to increase its product portfolio.

Industry Background

The first genome editing technology was developed in the late 1900s. Zinc Finger Nuclease, the first engineered nuclease technology was introduced, and has been extensively utilized for decades. However, this ZFNs technology turned outdated as it could not target definite nucleotide triplets that led to decline in specificity. In early 2000’s, TALENs was discovered that was more efficient as compared to the previously utilized ZFNs technology. Innovative genome editing tool namely, CRISPR was invented in 2009 that made DNA editing and development of gene therapy easier. Hence, rising usage of gene editing tool for developing advanced gene therapies will pave the way for significant market growth.